Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN37,7437,85-2,35
Msft204,1204,12-4,29
Nokia3,42153,463-3,05
IBM106,07106,14-4,03
Daimler AG44,1544,165-5,98
PFE35,6635,67-4,72
28.10.2020 18:24:49
Indexy online
AD Index online
select
AD Index online
 

  • 28.10.2020 18:24:27
Cytokinetics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
15,46 -5,33 -0,87 279 673
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.10.2020
Popis společnosti
Obecné informace
Název společnostiCytokinetics, Inc.
TickerCYTK
Kmenové akcie:Ordinary Shares
RICCYTK.O
ISIN-
Prioritní akciePreference Shares Series A
Prioritní akciePreference Shares Series B
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 156
Akcie v oběhu k 03.08.2020 70 504 701
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice280 E Grand Ave
MěstoSOUTH SAN FRANCISCO
PSČ94080-4808
ZeměUnited States
Kontatní osobaDiane Weiser
Funkce kontaktní osobyIR Contact Officer
Telefon16 506 243 000
Fax16506243010
Kontatní telefon16 506 243 060

Business Summary: Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator; AMG 594, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Cytokinetics, Inc. revenues decreased 52% to $7.4M. Net loss increased 30% to $80.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative increase of 38% to $26.6M (expense), Interest expense increase from $2.5M to $8M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 28.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardLeonard Patrick Gage7715.03.201015.03.2010
President, Chief Executive Officer, DirectorRobert Blum5622.01.2007
Chief Financial Officer, Senior Vice PresidentChing Jaw5626.06.201726.06.2017
Chief Human Resource Officer, Chief Administrative OfficerDavid Cragg64
Executive Vice President - Research and DevelopmentFady Malik5513.11.2015
Senior Vice President, General Counsel, SecretaryMark Schlossberg59
Chief Accounting Officer, Vice PresidentRobert Wong5215.05.201915.05.2019